Sarah Young (Nielsen), MS, CGC, Clinical Program Manager, Germline Oncology, is a board-certified genetic counselor with nearly 15 years of experience. She was previously a genetic counselor, clinical researcher and assistant director at the University of Chicago Center for Clinical Cancer Genetics. At Labcorp, she leads internal and external hereditary cancer research efforts, with a particular interest in prostate and genitourinary cancers and the intersection of germline and somatic testing.
Area of expertise: Molecular Genetics and Genomics, Molecular Oncology
Board Certifications: Certified Genetic Counselor (CGC)
Publications:
- Nielsen, S. M. et al. Utilization of cancer screening, prevention, and treatment in women with variants of uncertain significance in breast cancer susceptibility genes. J. Natl. Compr. Canc. Netw. 2025; 1, 1–7.
- Shore, N., Nielsen SM…et al. Implementation of universal germline genetic testing into standard of care for patients with prostate cancer: The time is now. JCO Oncol. Pract. 2024; doi:10.1200/op-24-00626.
- Shore, ND…Nielsen SM. Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients. Prostate Cancer Prostatic Dis. 1–7 (2025).
- Shore, N…Nielsen SM, Esplin ED. Clinician-reported management recommendations in response to universal germline genetic testing in patients with prostate cancer. J. Urol. 2024;101097JU0000000000004190.
- Wyatt Castillo, RB, Nielsen SM, Chen E, et al. Disparate Rates of Germline Variants in Cancer Predisposition Genes in African American/Black Compared With Non-Hispanic White Individuals Between 2015 and 2022. JCO Precis Oncol 2024; 8, e2300715.
- Shelton C…Nielsen SM. Universal Germline Genetic Testing for Breast Cancer: Implementation in a Rural Practice and Impact on Shared Decision Making. Ann Surg Oncol; 2024 Jan;31(1):325-334.
- Shore N…Nielsen SM, Esplin ED. Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial. Eur Urol Oncol; 2023; doi:10.1016/j.euo. 2023.07.008